Fenofibrate and Multiple sclerosis relapse - a phase IV clinical study of FDA data

Summary:

Multiple sclerosis relapse is reported as a side effect among people who take Fenofibrate (fenofibrate), especially for people who are female, 50-59 old, also take Ampyra, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Multiple sclerosis relapse when taking Fenofibrate. It is created by eHealthMe based on reports of 39,402 people who have side effects when taking Fenofibrate from the FDA, and is updated regularly.

What is Fenofibrate?

Fenofibrate has active ingredients of fenofibrate. It is often used in high blood cholesterol. eHealthMe is studying from 40,456 Fenofibrate users. Check the latest studies of Fenofibrate.

What is Multiple sclerosis relapse?

Multiple sclerosis relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,033 drugs and 943 conditions by eHealthMe. Check the latest studies of Multiple sclerosis relapse.

On Jul, 24, 2026

39,402 people reported to have side effects when taking Fenofibrate.
Among them, 101 people (0.26%) have Multiple sclerosis relapse.

Could Fenofibrate cause Multiple sclerosis relapse?

Among these 101 people:

What is the gender of people who have Multiple sclerosis relapse when taking Fenofibrate? *

Click here to view

What is the age of people who have Multiple sclerosis relapse when taking Fenofibrate? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Fenofibrate and have Multiple sclerosis relapse?

- Check whether Multiple sclerosis relapse is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Fenofibrate:

Fenofibrate (40,456 reports)

Multiple sclerosis relapse treatments and more:

Multiple sclerosis relapse (89,124 reports)

How severe was Multiple sclerosis relapse and when was it recovered:

Multiple sclerosis relapse in Fenofibrate

Expand to all the drugs that have ingredients of fenofibrate:

Multiple sclerosis relapse and drugs with ingredients of fenofibrate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Fenofibrate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Multiple sclerosis relapse:

Multiple sclerosis relapse (1,033 drugs)

Browse all the conditions that are associated with Multiple sclerosis relapse:

Multiple sclerosis relapse (943 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fenofibrate (the active ingredients of Fenofibrate) and Fenofibrate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.